A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Unresectable or Metastatic Breast Cancer

Interventions

DRUG

HRS-2189

DRUG

Fluvustat

DRUG

HRS-8080

DRUG

HRS-6209

DRUG

HRS-1358

Trial Locations (2)

RECRUITING

Harbin Medical University Affiliated Cancer Hospital, Harbin

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY